Dr. Raimon Sabate created the Conformational Diseases Group in the Department of Physical Chemistry of the Faculty of Pharmacy at the UB, which he leads as an Associate Professor. He studied Pharmacy at the University of Barcelona, where he received his PhD in Pharmacy in the field of Physical Chemistry. He subsequently went to the Institut de Biochimie et Génétique Cellulaires (IBGC—CNRS) in Bordeaux (France) with an MEC-Fulbright grant. He then returned to Barcelona, at the Institut de Biotecnologia i de Biomedicina (IBB—UAB), thanks to a Beatriu de Pinós postdoctoral fellowship. He is a biochemist experienced in the study of amyloid aggregation and conformational diseases, such as Alzheimer’s disease, Parkinson’s disease spongiform encephalopathy, and other prion and prion-like diseases. He recently developed new fast, simple, and cheap methods to screen potential inhibitors of amyloid aggregation which use prokaryotic and eukaryotic models (bacteria or yeast and fungus). These tests are much more rapid and cost-effective than in vivo studies which use transgenic animals.
Dr. Raimon Sabate created the Conformational Diseases Group in the Department of Physical Chemistry of the Faculty of Pharmacy at the UB, which he leads as an Associate Professor. He studied Pharmacy at the University of Barcelona, where he received his PhD in Pharmacy in the field of Physical Chemistry. He subsequently went to the Institut de Biochimie et Génétique Cellulaires (IBGC—CNRS) in Bordeaux (France) with an MEC-Fulbright grant. He then returned to Barcelona, at the Institut de Biotecnologia i de Biomedicina (IBB—UAB), thanks to a Beatriu de Pinós postdoctoral fellowship. He is a biochemist experienced in the study of amyloid aggregation and conformational diseases, such as Alzheimer’s disease, Parkinson’s disease spongiform encephalopathy, and other prion and prion-like diseases. He recently developed new fast, simple, and cheap methods to screen potential inhibitors of amyloid aggregation which use prokaryotic and eukaryotic models (bacteria or yeast and fungus). These tests are much more rapid and cost-effective than in vivo studies which use transgenic animals.